MedTrace Logo

Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation

NCT06793410 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-06-05

No results posted yet for this study

Summary

Patients who undergo allogeneic stem cell transplantation lose previously acquired immunity and are routinely revaccinated against many infectious diseases. For several reasons, these patients have a long-term immune deficiency due to the transplant itself (lack of immune reconstitution) and due to possible complications, primarily GvHD and its treatment. The risk of secondary malignancy in the long-term following an allogeneic bone marrow transplant is greatly increased, and secondary cancer cases account for a significant proportion of late deaths in both women and men after transplantation. Some of these secondary cancers are associated with HPV. The risk of cervical cancer has been reported to be 13 times increased compared to a healthy population.

Therefore in this trial, the aim is to study immune response (antigen-specific antibody response) after vaccination with 9-valent HPV vaccine (Gardasil 9®) in adult women and men (up to and including 45 years of age) who have undergone allogeneic stem cell transplantation. In this trial, the sponsor will compare "early" (start 9 months after tx) with "late" (start 15 months after tx) vaccination.

Conditions

  • Recipients of Allogeneic Stem Cell Transplantation
  • HPV (Human Papillomavirus)-Associated
  • Acute Myeloid Leukaemia
  • Myelodysplastic Syndrome
  • Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

BIOLOGICAL

Early start post-transplant vaccination with Gardasil 9®

Subjects will receive Gardasil 9® as part of the early post-transplant vaccination, starting at 9 months after transplantation.

BIOLOGICAL

Late post-transplant vaccination with Gardasil 9®

Subjects will receive Gardasil 9® as part of the late post-transplant vaccination, starting at 15 months after stem cell transplantation.

Sponsors & Collaborators

  • Vastra Gotaland Region

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-12
Primary Completion
2029-10-31
Completion
2029-10-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06793410 on ClinicalTrials.gov